Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Sept 2007

Hsieh Pin-Pen, Olsen Randy J, O'Malley Dennis P, Konoplev Sergej N, Hussong Jerry W, Dunphy Cherie H, Perkins Sherrie L, Cheng Liang, Lin Pei, Chang Chung-Che

Abstract excerpt

Extramedullary hematopoiesis (EMH) in the spleen is a characteristic feature of the chronic myeloproliferative disorders (CMPDs) and various other neoplastic or reactive myeloid conditions. However, the origin of these hematopoietic precursor cells and the molecular mechanisms underlying their de...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-X Protein
Share to Lasers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelomonocytic, Chronic

Share to Megakaryocytes

Share to Microdissection

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 17643100
DOI: 10.1038/modpathol.3800826

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17643100-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.PMID 17643100Read ↗

Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.Semantic proximity Read ↗

Oncogenic mechanisms in myeloproliferative disorders.Semantic proximity Read ↗

JAK2 in myeloproliferative disorders is not just another kinase.Semantic proximity Read ↗

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromesSemantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.Semantic proximity Read ↗

Janus kinase mutations.Semantic proximity Read ↗

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.Semantic proximity Read ↗

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.Semantic proximity Read ↗

JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.Semantic proximity Read ↗

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.